| Not Yet Recruiting | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy NCT05896371 | CHU de Quebec-Universite Laval | Phase 1 / Phase 2 |
| Not Yet Recruiting | Evaluating Interventional Radiology for Cancer Pain Management NCT07529314 | Hospices Civils de Lyon | N/A |
| Not Yet Recruiting | Real-world Trial of Individualized Precision Oncology NCT07346209 | University of California, San Diego | Phase 2 |
| Recruiting | Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer NCT07197671 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer NCT07432295 | I-Mab Biopharma US Limited | Phase 2 |
| Not Yet Recruiting | Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy NCT06828588 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Recruiting | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas NCT06346197 | Centre Leon Berard | Phase 3 |
| Recruiting | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study NCT07269080 | University of Illinois at Chicago | Phase 1 |
| Not Yet Recruiting | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases NCT07043608 | Kelly Fitzgerald, MD | Phase 2 |
| Recruiting | Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. NCT07144085 | Yi Tian | Phase 1 |
| Not Yet Recruiting | CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer NCT07057349 | Cytosite Biopharma Inc. | Phase 1 |
| Recruiting | Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer NCT06963723 | Alliance Foundation Trials, LLC. | N/A |
| Recruiting | PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival NCT06896162 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases NCT06311851 | Pardis Noor Medical Imaging and Cancer Center | Phase 1 / Phase 2 |
| Recruiting | COBRA: Cancer, Older Adults, Balance and Resistance Activities NCT07011862 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patie NCT06993987 | University Hospital, Brest | — |
| Recruiting | Comparison of Whole Body DWI to FDG PET NCT06630845 | University of California, San Francisco | N/A |
| Not Yet Recruiting | A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patient NCT06363773 | Elsan | N/A |
| Recruiting | PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer NCT06652607 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in NCT06693687 | M.D. Anderson Cancer Center | N/A |
| Not Yet Recruiting | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Col NCT06593548 | Fudan University | Phase 2 |
| Terminated | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic So NCT06540066 | BeiGene | Phase 1 |
| Recruiting | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors NCT06533059 | Alterome Therapeutics, Inc. | Phase 1 |
| Recruiting | Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors NCT06416007 | University of Cincinnati | Phase 2 |
| Recruiting | Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound His NCT06524570 | UMC Utrecht | Phase 1 |
| Recruiting | Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048 | Weijia Fang, MD | Phase 1 |
| Recruiting | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer NCT06275958 | Leiden University Medical Center | Phase 3 |
| Recruiting | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors NCT06190886 | Proviva Therapeutics, Inc. | Phase 1 |
| Recruiting | Biomarkers to Detect Endocrine Therapy Resistance NCT06067503 | University of Wisconsin, Madison | Phase 2 |
| Recruiting | UNC Metastatic Cancer Radiation Therapy Registry NCT06306924 | UNC Lineberger Comprehensive Cancer Center | — |
| Recruiting | Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas NCT06389123 | University of California, Davis | Phase 1 |
| Active Not Recruiting | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer NCT06107868 | University Health Network, Toronto | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Completed | Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment NCT06557967 | Daiichi Sankyo | — |
| Recruiting | Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases NCT06230666 | Matthias Guckenberger | N/A |
| Active Not Recruiting | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) NCT05853575 | Mirati Therapeutics Inc. | Phase 2 |
| Recruiting | Evaluating Disparities in Precision Oncology NCT06081517 | Indiana University | — |
| Unknown | A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors NCT06186427 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologi NCT06215950 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) NCT06174987 | Daiichi Sankyo | Phase 3 |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Recruiting | Definitive Radiation for High-Risk Spine Metastases NCT06165419 | Stony Brook University | Phase 2 |
| Recruiting | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035 | Spago Nanomedical AB | Phase 1 / Phase 2 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumo NCT06010875 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases NCT05789589 | Baptist Health South Florida | Phase 1 / Phase 2 |
| Recruiting | FIH XON7 in Advanced/Metastatic Solid Tumors NCT06154291 | Xenothera SAS | Phase 1 / Phase 2 |
| Recruiting | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents NCT06090266 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7 NCT06508138 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Tria NCT05508464 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Recruiting | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer NCT06058988 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Metastases Directed Therapy for Oligometastatic Breast Cancer NCT06144346 | National Cancer Institute, Egypt | N/A |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of ART0380 in Patients With Biologically Selected Solid Tumors NCT05798611 | Artios Pharma Ltd | Phase 2 |
| Unknown | Rurality Adapted Physical Activity Sport Health NCT05981170 | Institut Cancerologie de l'Ouest | — |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Terminated | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Can NCT05840510 | Mirati Therapeutics Inc. | Phase 1 |
| Suspended | Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet NCT05351294 | Rutgers, The State University of New Jersey | Phase 3 |
| Active Not Recruiting | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimbereli NCT05335941 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy NCT05831579 | Washington University School of Medicine | N/A |
| Withdrawn | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy NCT05574504 | AdventHealth | Phase 2 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Can NCT05301881 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080 | Incyclix Bio | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Ca NCT05669482 | Verastem, Inc. | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patien NCT05665348 | Federation Francophone de Cancerologie Digestive | Phase 2 / Phase 3 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers NCT05686226 | Christian Hinrichs | Phase 2 |
| Recruiting | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cance NCT05065736 | Roberto Vargas | EARLY_Phase 1 |
| Unknown | High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor NCT05755009 | Jiangxi Provincial Cancer Hospital | N/A |
| Terminated | Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies NCT05408871 | Yale University | Phase 1 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer NCT05502315 | Rana McKay, MD | Phase 2 |
| Unknown | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer NCT05802420 | Peking Union Medical College Hospital | N/A |
| Recruiting | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors NCT05544240 | Williams Cancer Foundation | Phase 1 |
| Completed | A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm NCT05555342 | University of California, Irvine | EARLY_Phase 1 |
| Unknown | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer NCT05904457 | Asan Medical Center | Phase 2 |
| Recruiting | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance NCT06121700 | Fudan University | Phase 2 |
| Completed | Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan NCT06504719 | Hellenic Cooperative Oncology Group | — |
| Recruiting | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) NCT05475171 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the H NCT05271604 | BioAtla, Inc. | Phase 2 |
| Unknown | The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Ca NCT05560035 | General Hospital of Ningxia Medical University | N/A |
| Recruiting | Patient Reported Outcomes/Metrics Program Trial NCT04983199 | University Health Network, Toronto | — |
| Recruiting | Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prosta NCT04612907 | Umeå University | N/A |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Recruiting | CALM Psychotherapy in Patients With Metastatic Cancer in Chile NCT06501261 | Fundacion Arturo Lopez Perez | N/A |
| Recruiting | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitog NCT05557045 | Jazz Pharmaceuticals | Phase 1 |
| Active Not Recruiting | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer NCT05566574 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II NCT05525858 | Seoul National University Bundang Hospital | — |
| Recruiting | Prospective Validation of a Points Score System Predicting 30-day Survival NCT05100342 | Indiana University | — |
| Completed | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy NCT05276284 | Kristoffer Rohrberg | Phase 1 / Phase 2 |
| Recruiting | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and NCT05378425 | Nectin Therapeutics Ltd | Phase 1 |
| Recruiting | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors NCT05394103 | Qurient Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal T NCT05489237 | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | Phase 1 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients NCT05375994 | Verastem, Inc. | Phase 1 / Phase 2 |
| Recruiting | First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid NCT05495295 | Phost'In Therapeutics | Phase 1 |
| Completed | Balancing Method for Pain Related to Advanced Cancer NCT04176575 | University of Pittsburgh | N/A |
| Not Yet Recruiting | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. NCT05422911 | James J. Peters Veterans Affairs Medical Center | Phase 2 |
| Recruiting | Implementing Precision Medicine in cOmmunity HospiTALs NCT05283044 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Recruiting | Comprehensive Outcomes for After Cancer Health NCT05349227 | Pack Health | N/A |
| Recruiting | Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 NCT05205200 | Fudan University | Phase 2 |
| Recruiting | Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metasta NCT05204147 | City of Hope Medical Center | Phase 1 |
| Completed | Towards an Early Integration of Palliative Care in Oncology NCT05339945 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474 | Weprom | — |
| Terminated | A Study of DS-9606a in Patients With Advanced Solid Tumors NCT05394675 | Daiichi Sankyo | Phase 1 |
| Recruiting | Parental Support Intervention in an Advanced Oncological Context NCT07341815 | Université Libre de Bruxelles | N/A |
| Withdrawn | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With NCT04931420 | University of Chicago | Phase 2 |
| Terminated | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adu NCT05346484 | Imugene Limited | Phase 1 |
| Completed | Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endo NCT05364905 | ARCAGY/ GINECO GROUP | — |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Recruiting | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer NCT05352178 | Universitaire Ziekenhuizen KU Leuven | Phase 3 |
| Completed | Trial of Written Exposure for Metastatic Cancer Patients (EASE) NCT06042400 | University of Colorado, Boulder | N/A |
| Active Not Recruiting | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal NCT05208047 | Cogent Biosciences, Inc. | Phase 3 |
| Completed | Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) NCT05165433 | Akamis Bio | Phase 1 |
| Active Not Recruiting | Niraparib in Tumors Metastatic to the CNS NCT04992013 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unrese NCT05267626 | Aulos Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Terminated | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors NCT05169437 | Tempus AI | Phase 2 |
| Completed | Ubuntu - I Am Because We Are NCT05314179 | University of Pittsburgh | N/A |
| Completed | Advance Care Planning in the Emergency Department NCT05209880 | Brigham and Women's Hospital | N/A |
| Completed | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in NCT05082610 | Hummingbird Bioscience | Phase 1 |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN NCT05260671 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Recruiting | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzu NCT05143970 | Institut Paoli-Calmettes | Phase 1 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect NCT04683939 | BioNTech SE | Phase 1 / Phase 2 |
| Completed | Holmium-166 Retrospective Collection of Real-World Data NCT05111795 | Terumo Europe N.V. | — |
| Recruiting | Metastatic Pathologic Fractures, Short Term Results NCT05825456 | Ankara University | — |
| Withdrawn | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery NCT04105062 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours NCT05043714 | Akamis Bio | Phase 1 |
| Active Not Recruiting | Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients NCT06193993 | National University Hospital, Singapore | Phase 1 |
| Active Not Recruiting | Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Pat NCT05032092 | Medical University of Graz | N/A |
| Unknown | An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for NCT05438342 | Shanghai Pudong Hospital | N/A |
| Recruiting | OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer NCT04680260 | Karen-Lise Garm Spindler | Phase 2 |
| Withdrawn | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma NCT04895046 | Walid Shaib, MD | Phase 2 |
| Terminated | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibito NCT04738292 | University of Wisconsin, Madison | Phase 2 |
| Active Not Recruiting | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarc NCT04862260 | CHU de Quebec-Universite Laval | EARLY_Phase 1 |
| Recruiting | Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic NCT04989725 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Terminated | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma NCT05036681 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Advanced Planning for Online Accounts and Data NCT05222308 | University of Colorado, Denver | N/A |
| Active Not Recruiting | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma NCT05010629 | Glenn J. Hanna | Phase 2 |
| Completed | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors NCT04991480 | Artios Pharma Ltd | Phase 1 |
| Unknown | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents NCT05094804 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Unknown | A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors NCT05315180 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Unknown | Dose Efficiency of Modern CT Scanners in Oncologic Scans NCT04989192 | University Hospital Augsburg | N/A |
| Recruiting | A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change NCT05010031 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Terminated | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) NCT04975256 | Mirati Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy NCT04868773 | University of California, Irvine | Phase 1 |
| Active Not Recruiting | A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Sp NCT05038124 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818 | I-Mab Biopharma US Limited | Phase 1 |
| Completed | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Ca NCT05007613 | National Taiwan University Hospital | Phase 2 |
| Completed | Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers NCT06083662 | Korea University Guro Hospital | Phase 2 |
| Completed | Feasibility of Supportive Care Needs in Patients With Advanced Solid Cancer in a Therapeutic Trial NCT04896099 | Institut Curie | — |
| Recruiting | A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories NCT05058937 | The Belgian Society of Medical Oncology | N/A |
| Recruiting | Liver Embolization Approaches for Tumor Management NCT05714124 | IRCCS San Raffaele | — |
| Active Not Recruiting | A Phase 2 Trial for Patients With Metastatic Solid Cancer NCT04713371 | Rampart Health, L.L.C. | Phase 2 |
| Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. NCT05610501 | Universitaire Ziekenhuizen KU Leuven | — |
| Unknown | Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Pati NCT04906733 | D1 Medical Technology (Shanghai) Co., Ltd, China | — |
| Unknown | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04859777 | Monopteros Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDA NCT03806309 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Unknown | Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO) NCT04793061 | Elisabethinen Hospital | — |
| Completed | Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophag NCT04920747 | Centre Hospitalier Universitaire de Besancon | — |
| Unknown | Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool. NCT05245136 | University Hospital Augsburg | — |
| Active Not Recruiting | Metastatic Solid Cancer Clinical Trial NCT04739618 | ImmunSYS, LLC | Phase 2 |
| Unknown | Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cance NCT03749850 | UMC Utrecht | Phase 1 |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Withdrawn | The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients NCT03003195 | University of Arkansas | Phase 2 |
| Terminated | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid NCT04725331 | Transgene | Phase 1 / Phase 2 |
| Completed | A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic T NCT04814667 | Centre Leon Berard | — |
| Unknown | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer NCT04641078 | University Hospital, Ghent | Phase 2 |
| Unknown | Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastati NCT04599608 | Imperial College London | — |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Unknown | Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors NCT04764409 | Central Clinical Hospital RZD-Medicine, Russian Federation | — |
| Completed | Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention NCT04773639 | University of Colorado, Boulder | N/A |
| Completed | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors NCT04678921 | I-Mab Biopharma US Limited | Phase 1 |
| Completed | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metast NCT04666688 | PureTech | Phase 1 / Phase 2 |
| Recruiting | FS222 First in Human Study in Patients With Advanced Malignancies NCT04740424 | invoX Pharma Limited | Phase 1 |
| Recruiting | Imaging of Solid Tumors Using FAP-2286 NCT04621435 | Thomas Hope | Phase 1 |
| Completed | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX- NCT04574583 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib NCT04770688 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Completed | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies NCT04672434 | Symphogen A/S | Phase 1 |
| Completed | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor NCT04648254 | Qurient Co., Ltd. | Phase 1 |
| Active Not Recruiting | FS120 Phase 1/1b Study in Patients With Advanced Malignancies NCT04648202 | invoX Pharma Limited | Phase 1 |
| Completed | ARREST - A Phase I Study of SABR for Poly-metastatic Disease NCT04530513 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Unknown | Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 NCT04604470 | Maastricht University | — |
| Completed | Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) NCT04606940 | University Health Network, Toronto | — |
| Completed | Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cance NCT04534218 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Completed | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advance NCT04641871 | Symphogen A/S | Phase 1 |
| Unknown | A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimburse NCT04641676 | The Belgian Society of Medical Oncology | N/A |
| Completed | Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Clo NCT04507828 | Indiana University | N/A |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Unknown | Immune Resistance Interrogation Study NCT04243720 | University Health Network, Toronto | — |
| Terminated | Study of GNX102 in Patients With Advanced Solid Tumors NCT04250597 | GlycoNex, Inc. | Phase 1 |
| Recruiting | Optimizing Y90 Therapy for Radiation Lobectomy NCT04390724 | Northwestern University | — |
| Recruiting | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers NCT04295863 | University of Chicago | Phase 1 |
| Completed | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors NCT04319757 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer NCT04355858 | Fudan University | Phase 2 |
| Withdrawn | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma NCT04184518 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Withdrawn | Systemic Chemotherapy Plus PD-1 for Metastasis ICC NCT04398927 | Sun Yat-sen University | Phase 2 |
| Recruiting | Immunotherapy for the Treatment of Advanced Solid Tumor NCT03658785 | Tongji Hospital | Phase 1 / Phase 2 |
| Unknown | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer NCT04380103 | Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Completed | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) NCT04330664 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC NCT04396886 | The University of Hong Kong | Phase 2 |
| Completed | Exercise Therapy in Radiation Therapy NCT03905356 | Milton S. Hershey Medical Center | N/A |
| Completed | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer NCT04208958 | Vedanta Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector NCT04053283 | Akamis Bio | Phase 1 |
| Terminated | S1916 Digital Medicine Program for Pain Control in Cancer Patients NCT04194528 | SWOG Cancer Research Network | N/A |
| Completed | Pembrolizumab in Biliary Tract Cancer NCT03260712 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Active Not Recruiting | HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; D NCT04257162 | SOLTI Breast Cancer Research Group | N/A |
| Active Not Recruiting | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistan NCT04090528 | University of Wisconsin, Madison | Phase 2 |
| Recruiting | Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry NCT04085029 | Duke University | — |
| Completed | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors NCT03954067 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC) NCT03868046 | Hospital Universitario Araba | — |
| Unknown | An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors NCT03864575 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Active Not Recruiting | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT03909334 | Xiuning Le | Phase 2 |
| Completed | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers NCT04050709 | ImmunityBio, Inc. | Phase 1 |
| Unknown | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer NCT03835949 | Tracon Pharmaceuticals Inc. | Phase 1 |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to NCT03941262 | NKGen Biotech, Inc. | Phase 1 |
| Unknown | Efficacy of Point Of Service Testing in MBC NCT03983577 | University of Kansas Medical Center | N/A |
| Completed | Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients NCT04714203 | Weprom | — |
| Completed | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors NCT03881488 | Compass Therapeutics | Phase 1 |
| Unknown | Crizotinib in ALK Rearranged Non-small-cell Lung Cancer NCT04317651 | Fondazione Ricerca Traslazionale | — |
| Completed | Predicting Disease Progression and/or Recurrence in Cancer NCT04776837 | Massachusetts General Hospital | — |
| Unknown | The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment NCT03873103 | The Belgian Society of Medical Oncology | — |
| Completed | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) NCT03852511 | Akamis Bio | Phase 1 |
| Unknown | ImmunoPET With an Anti-CD8 Imaging Agent NCT04029181 | University Medical Center Groningen | Phase 1 / Phase 2 |
| Completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors NCT03758781 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent NCT03829501 | Kymab Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 NCT03785249 | Mirati Therapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bo NCT03869762 | Cancer Trials Ireland | Phase 2 |
| Active Not Recruiting | An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking Ab NCT03794635 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Canc NCT03714958 | Centre Leon Berard | Phase 1 |
| Completed | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors NCT03689192 | Herlev Hospital | Phase 1 |
| Completed | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations NCT03570619 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention NCT03823313 | Indiana University | N/A |
| Active Not Recruiting | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy NCT03712566 | University Health Network, Toronto | — |
| Active Not Recruiting | Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell NCT03691714 | Trisha Wise-Draper | Phase 2 |
| Active Not Recruiting | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors NCT03693014 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer NCT03475004 | University of Colorado, Denver | Phase 2 |
| Withdrawn | Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Tr NCT03671720 | Capital Medical University | EARLY_Phase 1 |
| Unknown | Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood NCT03058809 | Viatar LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy NCT03391479 | University Health Network, Toronto | Phase 2 |
| Completed | Reducing Disparities in the Quality of Advance Care Planning for Older Adults NCT03516994 | Duke University | N/A |
| Unknown | Herzuma-capecitabine/Cisplatin for Gastric Cancer NCT03588533 | Sung Yong Oh | Phase 2 |
| Unknown | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma NCT03585673 | Sung Yong Oh | Phase 2 |
| Completed | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas NCT03489343 | Symphogen A/S | Phase 1 |
| Completed | Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Sol NCT03510104 | Meryx, Inc. | Phase 1 |
| Completed | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas NCT03489369 | Symphogen A/S | Phase 1 |
| Active Not Recruiting | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases NCT03569241 | University Hospital, Ghent | Phase 2 |
| Active Not Recruiting | Biomarkers of Immune-Related Toxicity NCT03409016 | University of Colorado, Denver | — |
| Terminated | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies NCT03440437 | invoX Pharma Limited | Phase 1 / Phase 2 |
| Completed | Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases NCT03757858 | Capital Medical University | Phase 1 / Phase 2 |
| Active Not Recruiting | RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3 NCT03375437 | Centre Leon Berard | N/A |
| Completed | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After NCT03356223 | Centre Leon Berard | Phase 2 |
| Completed | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostat NCT03392428 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Unknown | A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers NCT04710290 | E-DA Hospital | Phase 2 / Phase 3 |
| Terminated | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies NCT03277352 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Pa NCT03311412 | Symphogen A/S | Phase 1 |
| Completed | Electronic Patient Reporting of Symptoms During Cancer Treatment NCT03249090 | Alliance Foundation Trials, LLC. | N/A |
| Completed | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 NCT03307785 | Tesaro, Inc. | Phase 1 |
| Terminated | A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors NCT03295942 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor NCT03721055 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Completed | A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers NCT02919696 | Eli Lilly and Company | Phase 1 |
| Completed | Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO) NCT02857400 | Institut Claudius Regaud | N/A |
| Unknown | The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours NCT03863106 | Hospices Civils de Lyon | — |
| Unknown | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carci NCT03219775 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometast NCT03486431 | Cancer Research Antwerp | N/A |
| Terminated | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma NCT03024437 | Roberto Pili | Phase 1 / Phase 2 |
| Terminated | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer NCT03009058 | Immodulon Therapeutics Ltd | Phase 1 / Phase 2 |
| Completed | Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool NCT04143230 | A.O.U. Città della Salute e della Scienza | N/A |
| Completed | Mindfulness to Enhance Quality of Life and Support Advance Care Planning NCT03257007 | Indiana University | N/A |
| Unknown | Predictive Nomogram of CRPC NCT03177551 | Tianjin Medical University Second Hospital | — |
| Terminated | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT03119428 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies NCT03126110 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together Wi NCT03453892 | University of Erlangen-Nürnberg Medical School | — |
| Completed | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck NCT03132038 | UNICANCER | Phase 2 |
| Terminated | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) NCT02959437 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) NCT03013218 | ALX Oncology Inc. | Phase 1 |
| Completed | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer NCT03027284 | Eli Lilly and Company | Phase 1 |
| Unknown | Mobile Health Technology for Palliative Care Patients NCT03038841 | University of Zurich | — |
| Completed | Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology NCT03012139 | Mayo Clinic | — |
| Unknown | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor NCT03299452 | Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Completed | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic NCT02923349 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Unknown | Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics NCT02828462 | Gustave Roussy, Cancer Campus, Grand Paris | — |
| Active Not Recruiting | Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial) NCT02756793 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Completed | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients NCT02903914 | Incyte Corporation | Phase 1 |
| Completed | Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease NCT02843165 | University of California, San Diego | Phase 2 |
| Terminated | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) NCT02801097 | EpicentRx, Inc. | Phase 1 |
| Completed | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic NCT02860780 | Eli Lilly and Company | Phase 1 |
| Completed | Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer NCT03936205 | Hotel Dieu de France Hospital | Phase 2 / Phase 3 |
| Completed | A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors NCT02697591 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB NCT02777710 | Centre Leon Berard | Phase 1 |
| Active Not Recruiting | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer NCT02711553 | Eli Lilly and Company | Phase 2 |
| Withdrawn | Treat Primary and Metastatic Liver Tumors NCT05240040 | Methodist Health System | — |